ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer
Overall survival results from a study with a combination of [...]
ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer
The results from one of the first clinical trials of [...]
ASCO GU 2020: Adding radiotherapy to immunotherapy for the treatment of metastatic kidney cancer
Two clinical trials looking at the use of radiotherapy and [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Ilixadencel improves responses and survival in metastatic kidney cancer
Results from a recent phase 2 clinical trial of ilixadencel [...]
First-line treatment of papillary renal cell carcinoma with sunitinib
Papillary renal cell carcinoma (PRCC) is a rare subtype of [...]
NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
New risk scoring system for metastatic kidney cancer
The treatment options for metastatic renal cell carcinoma (RCC) have [...]
